|
1
|
Jemal A, Bray F, Center MM, Ferley J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Breastcancer.org. U.S. Breast Cancer
Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics.jsp.
Accessed December 21, 2011
|
|
3
|
Ali SM, Harvey HA and Lipton A: Metastatic
breast cancer: overview of treatment. Clin Orthop. 414:S132–S137.
2003. View Article : Google Scholar
|
|
4
|
Endometrial (Uterine) Cancer. What are the
key statistics about endometrial cancer? http://www.cancer.org/Cancer/EndometrialCancer/DetailedGuide/endometrial-uterine-cancer-key-statistics.
Accessed January 20, 2012
|
|
5
|
Ovarian Cancer National Alliance. Ovarian
Cancer Statistics. http://www.ovariancancer.org/about-ovarian-cancer/statsitics/.
Accessed December 28, 2011
|
|
6
|
Fidler IJ: Molecular biology of cancer:
invasion and metastasis. Cancer: Principles and Practice of
Oncology. De Vita VT, Hellman S and Rosenberg SA: 5th edition.
Lippincott-Raven; Philadelphia, PA: pp. 135–152. 1997
|
|
7
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29(Suppl 16): 15–18. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chambers AF and Matrisian LM: Changing
views on the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleiner DL and Stetler-Stevenson WG:
Matrix metalloproteinases and metastasis. Cancer Chemother
Pharmacol. 43:S42–S51. 1999. View Article : Google Scholar
|
|
11
|
Yurchenko PD and Schitny JC: Molecular
architecture of basement membranes. FASEB J. 4:1577–1590.
1990.PubMed/NCBI
|
|
12
|
Barsky SH, Siegel GP, Jannotta F and
Liotta LA: Loss of basement membrane components by invasive tumors
but not by their benign counterparts. Lab Invest. 49:140–147.
1983.PubMed/NCBI
|
|
13
|
Liotta LA, Tryggvason K, Garbisa A, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
15
|
Bérubé M, Deschambeault A, Boucher M,
Germain L, Petitclerc E and Guérin SL: MMP-2 expression in uveal
melanoma: differential activation status dictated by the cellular
environment. Mol Vis. 11:1101–1111. 2005.PubMed/NCBI
|
|
16
|
Garzetti G, Ciavattini A, Lucarini G,
Goteri G, de Nicolis M, Garbisa S, Masiero L, Romanini C and
Graziella B: Tissue and serum metalloproteinase (MMP-2) expression
in advanced ovarian serous cystadenocarcinomas: clinical and
prognostic implications. Anticancer Res. 15:2799–2804.
1995.PubMed/NCBI
|
|
17
|
Sugimura M, Kobayashi H, Kanayama N and
Terao T: Clinical significance of urokinase-type plasminogen
activator (uPA) in invasive cervical cancer of the uterus. Gynecol
Oncol. 46:330–336. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bachmeier BE, Nerlich AG, Lichtinghagen R
and Sommerhoff CP: Matrix metalloproteinases (MMPs) in breast
cancer cell lines of different tumorigenicity. Anticancer Res.
6A:3821–3828. 2001.PubMed/NCBI
|
|
19
|
Pellikainen JM, Ropponen KM, Kataja VV,
Kellokoski JK, Eskelinen MJ and Kosma VM: Expression of matrix
metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special
reference to activator protein-2, HER-2, and prognosis. Clin Cancer
Res. 10:7621–7628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scorilas A, Karameris A, Arnogiannaki N,
Ardavanis A, Bassilopoulos P, Tangas T and Tlieri M: Overexpression
of matrix-metalloproteinase-9 in human breast cancer: a potential
favourable indicator in node-negative patients. Br J Cancer.
84:1488–1496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Asha Nair S, Karunagaran D, Nair MB and
Sudhakaran PR: Changes in matrix metalloproteinases and their
endogenous inhibitors during tumor progression in the uterine
cervix. J Cancer Res Clin Oncol. 129:123–131. 2003.PubMed/NCBI
|
|
22
|
Zhou CY, Yao JF and Chen XD: Expression of
matrix metalloproteinase-2,9 and their inhibitor-TIMP 1,2 in human
squamous cell carcinoma of uterine cervix. Al Zhen. 21:735–739.
2002.PubMed/NCBI
|
|
23
|
Lopata A, Agresta F, Quinn MA, Smith C,
Ostor AG and Salamonsen LA: Detection of endometrial cancer by
determination of matrix metalloproteinases in the uterine cavity.
Gynecol Oncol. 90:318–324. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aglund K, Rauvala M, Puistola U, Angström
T, Turpeeniemi-Hujanen T, Zackrisson B and Stendahl U: Gelatinases
A and B (MMP-2 and MMP-9) in endometrial cancer - MMP-9 correlates
to the grade and the stage. Gynecol Oncol. 94:699–704. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Torng PL, Mao TL, Chan WY, Huang SC and
Lin CT: Prognostic significance of stromal metalloproteinase-2 in
ovarian adenocarcinoma and in relation to carcinoma progression.
Gynecol Oncol. 92:559–567. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Memarzedeh S, Kozak KR, Chang L, Natarajan
S, Shintaku P, Reddy ST and Farias-Eisner R: Urokinase plasminogen
activator receptor: prognostic biomarker for endometrial cancer.
Proc Natl Acad Sci USA. 99:10647–10652. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Steiner E, Pollow K, Hasenclever D,
Schormann W, Hermes M, Schmidt M, Puhl A, Brulport M, Bauer A,
Petry IB, Koelbl H and Hengstler JG: Role of urokinase-type
plasminogen activator (uPA) and plasminogen activator inhibitor
type 1 (PAI-1) for prognosis in endometrial cancer. Gynecol Oncol.
108:569–576. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI
|
|
29
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dano K, Andreasen PA, Grondahl-Hansen J,
Kristensen P, Nielsen LS and Skriver L: Plasminogen activators,
tissue degradation and cancer. Adv Cancer Res. 44:139–266. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alonso DF, Farias EF, Ladeda V, Davel L,
Puricelli L and Bal de Kier Joffé E: Effects of synthetic urokinase
on local invasion and metastasis in a murine mammary tumor model.
Breast Cancer Res Treat. 40:209–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duffy MJ, Duggan C, Mulcahy HE, McDermott
EW and O’Higgins NJ: Urokinase plasminogen activator: a prognostic
marker in breast cancer including patients with axillary
node-negative disease. Clin Chem. 44:1177–1183. 1998.PubMed/NCBI
|
|
33
|
Kuhn W, Pache L, Schmaltfeldt B, Dettmar
P, Schmitt M, Jänicke F and Graeff H: Urokinase (uPA) and Pal-1
predict survival in advanced ovarian cancer patients (FIGO III)
after radical surgery and platinum-based chemotherapy. Gynecol
Oncol. 55:401–409. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rath M and Pauling L: Plasmin-induced
proteolysis and the role of apoprotein(a), lysine and synthetic
analogs. J Orthomolecular Med. 7:17–23. 1992.
|
|
35
|
Andreasen PA, Kjøller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Niedzwiecki A, Roomi MW, Kalinovsky T and
Rath M: Micronutrient synergy - a new tool in effective control of
metastasis and other key mechanisms of cancer. Cancer Metastasis
Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roomi MW, Monterrey JC, Kalinovsky T,
Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a
nutrient mixture in human cancer cell lines: a correlation study.
Exp Oncol. 32:243–248. 2010.PubMed/NCBI
|
|
38
|
Roomi MW, Ivanov V, Kalinovsky T,
Niedzwiecki A and Rath M: In vitro and in vivo antitumorigenic
activity of a mixture of lysine, proline, ascorbic acid, and green
tea extract on human breast cancer lines MDA-MB-231 and MCF-7. Med
Oncol. 22:129–138. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Amin ARMR, Kucek O, Khuri FR and Shin DM:
Perspectives for cancer prevention with natural compounds. J Clin
Oncol. 27:2712–2725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
41
|
Sun Z, Chen YH, Wang P, Zhang J, Gurewich
V, Zhang P and Liu JN: The blockage of high-affinity lysine binding
sites of plasminogen by EACA significantly inhibits
prourokinase-induced plasminogen activation. Biochem Biophys Acta.
1596:182–192. 2002.PubMed/NCBI
|
|
42
|
Kemberling JK, Hampton JA, Keck RW, Gomez
MA and Selman SH: Inhibition of bladder tumor growth by the green
tea derivative epigallocatechin-3-gallate. J Urol. 170:773–776.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sato D and Matsushima M: Preventive
effects of urinary bladder tumors induced by
N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves.
Int J Urol. 10:160–166. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Valcic S, Timmermann BN, Alberts DS,
Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect
of six green tea catechins and caffeine on the growth of four
selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mukhtar H and Ahmed N: Tea polyphenols:
prevention of cancer and optimizing health. Am J Clin Nutr.
71:S1698–S1704. 2000.PubMed/NCBI
|
|
46
|
Yang GY, Liao J, Kim K, Yurtow EJ and Yang
CS: Inhibition of growth and induction of apoptosis in human cancer
cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Taniguchi S, Fujiki H, Kobayashi H, Go H,
Miyado K, Sadano H and Shimikawa R: Effect of (−) epigallocatechin
gallate, the main constituent of green tea, on lung metastasis with
mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992.
|
|
48
|
Hara Y: Green Tea: Health Benefits and
Applications. Marcel Dekker Inc; New York: 2001, View Article : Google Scholar
|
|
49
|
Kawakami S, Kageyama Y, Fujii Y, Kihara K
and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion
and MMP 9 production of T24 human bladder cancer cells. Anticancer
Res. 21:213–219. 2001.PubMed/NCBI
|
|
50
|
Morini M, Cai T, Aluigi MG, Noonan DM,
Masiello L, De Floro S, D’Agostinin F, Albini A and Fassima G: The
role of the thiol N-acetyl cysteine in the prevention of tumor
invasion and angiogenesis. Int J Biol Markers. 14:268–271.
1999.PubMed/NCBI
|
|
51
|
Yoon SO, Kim MM and Chung AS: Inhibitory
effects of selenite on invasion of HT 1080 tumor cells. J Biol
Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Naidu KA, Karl RC and Coppola D:
Antiproliferative and proapoptotic effect of ascorbyl stearate in
human pancreatic cancer cells: association with decreased
expression of insulin-like growth factor 1 receptor. Dig Dis Sci.
48:230–237. 2003. View Article : Google Scholar
|
|
53
|
Anthony HM and Schorah CJ: Severe
hypovitaminosis C in lung-cancer patients: The utilization of
vitamin C in surgical repair and lymphocyte-related host
resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Maramag C, Menon M, Balaji KC, Reddy PG
and Laxmanan S: Effect of vitamin C on prostate cancer cells in
vitro: effect on cell number, viability and DNA synthesis.
Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Koh WS, Lee SJ, Lee H, Park C, Park MH,
Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH:
Differential effects and transport kinetics of ascorbate
derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493.
1998.PubMed/NCBI
|
|
56
|
Chen Q, Espey MG, Krishna MC, Mitchell JB,
Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic
ascorbic acid concentrations selectively kill cancer cells: Action
as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl
Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nunez C, Ortiz de Apodaca Y and Ruiz A:
Ascorbic acid in the plasma and blood cells of women with breast
cancer. The effect of consumption of food with an elevated content
of this vitamin. Nutr Hosp. 10:368–372. 1995.(In Spanish).
|
|
58
|
Kurbacher CM, Wagner U, Kolster B,
Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C)
improves the antineoplastic activity of doxorubicin, cisplatin and
paclitaxel in human breast carcinoma cells in vitro. Cancer Lett.
103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cooke JP and Dzau VJ: Nitric oxide
synthase: Role in the genesis of vascular disease. Annu Rev Med.
48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Roomi MW, Ivanov V, Netke SP, Niedzwiecki
A and Rath M: Serum markers of the liver, heart, and kidney and
lipid profile and histopathology in ODS rats treated with nutrient
synergy. J AM Coll Nutr. 22:4772003.
|
